CSL Strikes Rare-Disease Drug Deal With Alentis Worth Up to $1.6 Billion
CSL will pay Alentis $355 million upfront to co-develop lixudebart, with potential commercial milestones lifting the deal’s value to about $1.6 billion.
Oz Asks Health Insurers to Use Brokers Who Record Marketplace Enrollment Calls
CMS Administrator Mehmet Oz says insurers are being asked to work with brokers who record Marketplace enrollment calls as the agency expands anti-fraud safeguards.
Greenwich Rx Recalls Injectable Glutathione Over Endotoxin Risk
Greenwich Rx is recalling 10 lots of compounded glutathione injection nationwide after testing indicated potentially elevated endotoxin levels.
Who Qualifies for the $90 Medicare Part B Rebate—and When It Arrives
A one-time $90 Medicare Part B rebate is due for about 20.8 million beneficiaries in October. Here is who qualifies, when payments arrive and what to do if one is…
FTC Urges Parents to Talk With Children About Deepfakes and Online Safety
The FTC's October consumer alert gives parents practical ways to discuss deepfakes, boundaries and how to seek help when an intimate image is shared.
Great Value and Trader Joe’s Frozen Berry Recall Expands
A frozen berry recall expanded to additional Great Value and Trader Joe's lots because of possible E. coli O145:H28 contamination.
FDA Plans 10 Cyclospora Prevention Steps After Record Lettuce Outbreak
The FDA announced 10 actions through the 2027 growing season after closing its investigation into a record Cyclospora outbreak linked to iceberg lettuce.
Stewart’s Recalls Two Ice Cream Flavors Over Possible Metal
Stewart's Shops recalled two half-gallon ice cream flavors sold in New York, Vermont and New Hampshire after a consumer found a metal object.
UnitedHealthcare and Aetna Narrow Some Medicare Advantage Networks for 2027
UnitedHealthcare and Aetna say more 2027 Medicare Advantage plans will limit provider access, making annual network checks especially important during open enrollment.
Foghorn and Lilly End FHD-909 Program; Biotech Plans 40% Workforce Cut
Foghorn Therapeutics and Eli Lilly will not advance the cancer drug FHD-909 after Phase 1 data review, and Foghorn says it will reduce its workforce by about 40%.